KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Share-based Compensation (2016 - 2025)

CareDx (CDNA) has disclosed Share-based Compensation for 13 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 51.0% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.9 million through Dec 2025, down 47.5% year-over-year, with the annual reading at $34.9 million for FY2025, 47.5% down from the prior year.
  • Share-based Compensation hit $8.1 million in Q4 2025 for CareDx, down from $8.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $16.9 million in Q3 2024 to a low of $6.5 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $11.6 million across 5 years, with a median of $10.9 million in 2021.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 65.76% in 2024 and later plummeted 51.0% in 2025.
  • Year by year, Share-based Compensation stood at $9.5 million in 2021, then rose by 27.67% to $12.1 million in 2022, then decreased by 17.85% to $10.0 million in 2023, then surged by 65.76% to $16.5 million in 2024, then tumbled by 51.0% to $8.1 million in 2025.
  • Business Quant data shows Share-based Compensation for CDNA at $8.1 million in Q4 2025, $8.4 million in Q3 2025, and $9.4 million in Q2 2025.